Log in or Sign up for Free to view tailored content for your specialty!
Liver/Biliary Disorders News
VIDEO: Resistant starch supplement lowers liver fat, alters gut microbiome in NAFLD
Dietary supplementation with resistant starch reduced intrahepatic triglyceride content and may help manage disease by altering gut microbiota among patients with nonalcoholic fatty liver disease, according to data in Cell Metabolism.
Liver disease causes 50% of all deaths in first 5 years after alcohol-related diagnosis
Liver disease was the primary cause of death in patients with alcohol-related liver disease several years after diagnosis, with the risk for mortality almost three times higher in those with decompensated cirrhosis, according to research.
Log in or Sign up for Free to view tailored content for your specialty!
Fibrosis-4 may be ‘better screening tool’ for advanced NAFLD fibrosis in lean patients
Although fibrosis-4 index and NAFLD fibrosis score did not significantly differ in diagnosing advanced fibrosis in nonalcoholic fatty liver disease, fibrosis-4 may be a better screening tool in lean patients, according to a study.
Q&A: Causes of hepatocellular carcinoma ‘differ remarkably’ by race, ethnicity
Rates of hepatocellular carcinoma caused by alcohol-related disease and nonalcoholic fatty liver disease are on the rise, especially among Hispanic individuals, according to research in Clinical Gastroenterology and Hepatology.
‘Ask me about PBC’ campaign calls on patients to speak up for rare liver disease
International Primary Biliary Cholangitis Day, celebrated on September 10, aspires to raise awareness of the challenges that patients with this rare liver disease face and how their stories can help advance diagnosis, treatment and care.
FDA grants orphan drug designation to inhaled therapy for alpha-1 antitrypsin deficiency
The FDA granted orphan drug designation for KB408 for the treatment of alpha-1 antitrypsin deficiency, according to a press release from Krystal Biotech.
High out-of-pocket costs may lower rifaximin adherence for hepatic encephalopathy
Researchers reported low rifaximin treatment retention among patients with hepatic encephalopathy, with 30-day out-of-pocket treatment costs in excess of $150 among the factors associated with poor adherence.
RESPONSE topline data: Seladelpar normalized alkaline phosphatase, reduced pruritus in PBC
Seladelpar reduced serum alkaline phosphatase and bilirubin at 12 months in more than 60% of patients with primary biliary cholangitis compared with 20% of placebo-treated patients, according to manufacturer, CymaBay Therapeutics.
Female surgeons have better outcomes in cholecystectomies but longer operating times
Female surgeons had fewer surgical and total complications in elective and acute care cholecystectomies but longer operating times compared with male surgeons, according to data in JAMA Surgery.
Former Smash Mouth singer’s death underscores need for liver disease awareness
After nearly a decade of health problems, Steve Harwell, former lead singer and frontman for the band Smash Mouth, died Sept. 4 at age 56, which the band’s manager, Robert Hayes, said was caused by acute liver failure.
-
Headline News
Expected drop in HIV care providers may signal potential shift to primary care physicians
November 11, 20242 min read -
Headline News
Q&A: What to know about surge of ‘walking pneumonia’ in children
November 09, 20244 min read -
Headline News
Racial gaps in preemptive living donor kidney transplant persist during last 2 decades
November 12, 20241 min read
-
Headline News
Expected drop in HIV care providers may signal potential shift to primary care physicians
November 11, 20242 min read -
Headline News
Q&A: What to know about surge of ‘walking pneumonia’ in children
November 09, 20244 min read -
Headline News
Racial gaps in preemptive living donor kidney transplant persist during last 2 decades
November 12, 20241 min read